Fursultiamine injection,
does it really help with Immediate fatigue relief and increased vitality in generally healthy adults without vitamin B1 deficiency?
research showsThe grade is ? because no completed human intervention trial was found that directly tested fursultiamine injection for immediate fatigue relief or vitality in generally healthy adults without vitamin B1 deficiency. Human studies in healthy people addressed oral pharmacokinetics or intravenous PET distribution in three participants, not fatigue efficacy. Evidence for deficiency treatment, animal activity, other routes, or other diseases was not repurposed for this claim, and the score is null.
ads claimA distinctive post-injection smell or sensation, thiamine's biochemical role in energy metabolism, and benefit in deficiency are connected to immediate fatigue recovery in nondeficient people. Biochemical plausibility does not replace a clinical efficacy trial.
Useful facts when choosing a product
- Fursultiamine is a lipid-soluble vitamin B1 derivative also called thiamine tetrahydrofurfuryl disulfide or TTFD.
- This verdict is limited to injected fursultiamine for immediate fatigue and vitality in nondeficient adults and is separate from deficiency treatment or other indications for oral thiamine or benfotiamine.
- Injection-site pain and inflammation, nausea, dizziness, allergy, rare anaphylaxis, infection from poor sterility, and self-pay cost are relevant.
- Persistent fatigue warrants evaluation for anemia, thyroid disease, sleep disorders, infection, depression or anxiety, medicines, and other causes.
What the research actually shows
Kitamori 1993 measured blood thiamine pharmacokinetics after oral TTFD 10 and 100 mg in healthy adults without assessing fatigue. Watanabe 2021 intravenously administered carbon-11-labeled TTFD to three healthy young men to measure organ distribution and radiation dosimetry, with no clinical fatigue or vitality outcome. Animal voluntary-activity research and deficient-patient reports address different populations and outcomes.
Why this is classified as ?
No completed human efficacy intervention was identified for the claimed formulation, population, and outcome. Pharmacokinetic, distribution, and deficiency-treatment evidence was not repurposed, giving ? with a null score.
Counterpoint. Appropriate thiamine treatment matters when genuine deficiency or high risk is present, but that is a separate diagnostic and therapeutic question.
Rejudgment record. New verdict — Applied boundary rule ④ because no completed human intervention was found for injected fursultiamine in generally healthy nondeficient adults with immediate fatigue relief or vitality outcomes; oral pharmacokinetics, intravenous PET distribution, deficiency treatment, and animal evidence were not repurposed
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Immediate fatigue relief | ? | No human intervention was found directly testing injected fursultiamine in nondeficient adults. |
| Increased vitality and energy | ? | Pharmacokinetics and energy-metabolism mechanisms are not clinical vitality outcomes. |
| Benefit in generally healthy nondeficient adults | ? | Deficiency-treatment evidence cannot be transferred to a nondeficient population. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kitamori N, Itokawa Y. 1993 | Oral pharmacokinetic study in healthy adults | 100 | Study from Takeda pharmaceutical development laboratories | Blood thiamine concentrations and pharmacokinetics | Blood thiamine increased after oral TTFD, but injection, fatigue, and vitality were not evaluated. | Exposure evidence, not evidence for the claimed efficacy |
| Watanabe Y et al. 2021 | First-in-human intravenous PET distribution and dosimetry study | 3 | RIKEN and academic research | Whole-body distribution and radiation dosimetry of carbon-11 TTFD | Organ distribution after intravenous administration was characterized, with no clinical fatigue or vitality outcome. | Intravenous exposure evidence, not an efficacy trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Fursultiamine injection x immediate fatigue relief and vitality in nondeficient adults — Evidence Grade ?. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/fursultiamine-injection-fatigue-vitality-nondeficient-adults/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.